Long-term results from the COMPASSION-03 trial show that cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, offers lasting survival benefits for patients with recurrent or metastatic cervical cancer who have failed prior chemotherapy.
Patients who achieved complete responses had a 100% survival rate at 24 months, while partial responders showed a 63% survival rate, with a median progression-free survival of 11.2 months. Overall, the median survival for all patients was 17.5 months, with about 41% alive at two years.
Cadonilimab works independently of PD-L1 status, making it effective in both “hot” and “cold” tumors. Its bispecific design targets PD-1 and CTLA-4 in one molecule, aiming to combine the benefits of dual immunotherapy with a safer profile than giving two separate drugs. The trial included heavily pretreated patients, showing robust activity even in those with multiple prior therapies. Already approved in China for gastric and cervical cancers, cadonilimab is now being evaluated in 11 Phase 3 trials worldwide to expand its use across cancer types.